Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest NeuroSigma Inc. Stories

2014-04-01 08:28:00

LOS ANGELES, April 1, 2014 /PRNewswire/ -- NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration (TGA) to market its Monarch(TM) eTNS(TM) System in Australia. The approval allows NeuroSigma to market the Monarch eTNS System for the adjunctive...

2014-03-28 08:26:16

Carl Adams Promoted to Chief Financial Officer and Craig Rostamian Joins as Vice President of Finance LOS ANGELES, March 28, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the promotion of Carl Adams to Chief Financial Officer (CFO) and the appointment of Craig Rostamian as Vice President...

2014-02-25 08:31:10

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of David Hayes, Esq. as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary. Prior to joining NeuroSigma, Mr. Hayes was a partner at Hayes and Boone, LLP, since...

2014-02-11 08:30:26

LOS ANGELES, Feb. 11, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of Carl Adams as Vice President and Controller. Mr. Adams brings 20 years of experience in accounting and corporate finance to NeuroSigma. After nine years at Ernst and Young LLP, culminating as a...

2014-01-27 08:26:10

LOS ANGELES, Jan. 27, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurologic and neuropsychiatric disorders, today announced the appointment of Gregory F. Brooks as Senior Vice President and Chief Commercial Officer. Mr. Brooks brings more than 30 years of experience in the pharmaceutical, biologic and medical device industries to...

2014-01-21 04:22:08

LOS ANGELES, Jan. 21, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, today announced that two presentations were made last month at the annual American Epilepsy Society meeting held in Washington, DC, which reported positive results using external Trigeminal Nerve Stimulation (eTNS(TM)) for the adjunctive treatment of epilepsy. In the first presentation, Lina Nashef, M.D., Consultant Neurologist and Honorary Reader at King's College...

2013-12-05 08:28:42

LOS ANGELES, Dec. 5, 2013 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/898,675 entitled "Systems, Devices and Methods For Treatment of Neurological Disorders and Conditions." The patent application, exclusively licensed to NeuroSigma, is owned by The Regents of the University of California (Regents) as a...

2013-07-29 08:25:55

External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy LOS ANGELES, July 29, 2013 /PRNewswire/ -- NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE) application to commence a Phase III pivotal trial of the Monarch(TM) eTNS(TM) System for treatment of drug resistant epilepsy. The Company is planning to conduct a multi-center trial at leading medical institutions in...

2013-06-21 08:24:41

NeuroSigma Will Sponsor a Satellite Symposium at the International Epilepsy Congress In Montreal, June 23-27th 2013 LOS ANGELES, June 21, 2013 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch(TM) eTNS(TM) System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30(th) International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013. The Monarch eTNS...

2013-06-06 08:28:58

Comprehensive Clinical and Product Information for Patients and Physicians in the European Union and Canada LOS ANGELES, June 6, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the Monarch(TM) eTNS(TM) System. The new site provides a comprehensive resource for those in the European Union and Canada who are considering use of the non-invasive Monarch system to treat their...